1. Home
  2. DOMH vs SNGX Comparison

DOMH vs SNGX Comparison

Compare DOMH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMH
  • SNGX
  • Stock Information
  • Founded
  • DOMH 1967
  • SNGX 1987
  • Country
  • DOMH United States
  • SNGX United States
  • Employees
  • DOMH N/A
  • SNGX N/A
  • Industry
  • DOMH Biotechnology: Pharmaceutical Preparations
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOMH Health Care
  • SNGX Health Care
  • Exchange
  • DOMH Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • DOMH 8.8M
  • SNGX 7.4M
  • IPO Year
  • DOMH N/A
  • SNGX 1987
  • Fundamental
  • Price
  • DOMH $3.02
  • SNGX $2.32
  • Analyst Decision
  • DOMH
  • SNGX
  • Analyst Count
  • DOMH 0
  • SNGX 0
  • Target Price
  • DOMH N/A
  • SNGX N/A
  • AVG Volume (30 Days)
  • DOMH 427.5K
  • SNGX 620.7K
  • Earning Date
  • DOMH 03-31-2025
  • SNGX 03-14-2025
  • Dividend Yield
  • DOMH N/A
  • SNGX N/A
  • EPS Growth
  • DOMH N/A
  • SNGX N/A
  • EPS
  • DOMH N/A
  • SNGX N/A
  • Revenue
  • DOMH $12,589,000.00
  • SNGX $364,183.00
  • Revenue This Year
  • DOMH N/A
  • SNGX N/A
  • Revenue Next Year
  • DOMH N/A
  • SNGX $76.64
  • P/E Ratio
  • DOMH N/A
  • SNGX N/A
  • Revenue Growth
  • DOMH 1117.50
  • SNGX N/A
  • 52 Week Low
  • DOMH $0.83
  • SNGX $0.32
  • 52 Week High
  • DOMH $4.35
  • SNGX $14.83
  • Technical
  • Relative Strength Index (RSI)
  • DOMH 65.22
  • SNGX 36.12
  • Support Level
  • DOMH $2.86
  • SNGX $2.23
  • Resistance Level
  • DOMH $4.35
  • SNGX $2.39
  • Average True Range (ATR)
  • DOMH 0.52
  • SNGX 0.17
  • MACD
  • DOMH 0.14
  • SNGX 0.01
  • Stochastic Oscillator
  • DOMH 53.19
  • SNGX 22.12

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: